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ABSTRACT  
Background: Impulse oscillometry (IOS) has previously been proposed to provide greater 
sensitivity than spirometry when employed with indirect bronchoprovocation testing for the 
diagnosis of airway dysfunction in athletes. However, this recommendation is based on a highly 
selected population of symptomatic patients. Objective: To compare IOS, spirometry and 
respiratory symptoms following indirect bronchoprovocation in a screened cohort of athletes. 
Methods: One hundred and one recreational athletes were recruited. Respiratory symptoms 
were assessed via the Dyspnoea-12 questionnaire. Spirometry and IOS were performed pre-and 
post- a eucapnic voluntary hyperpnoea (EVH) challenge. Results: Ninety-four athletes 
completed the study. Sixteen athletes (17%) were positive for airway dysfunction based on 
spirometry (i.e. ≥10% fall in FEV1) and seventeen athletes (18%) based on IOS (i.e. ≥50% 
increase in R5). Only nine athletes (10%) met both diagnostic thresholds. A poor relationship 
was observed between respiratory symptoms (i.e. Dyspnoea-12 score) and all spirometry and 
IOS variables. A direct relationship was observed between percentage change in R5 (r = 0.65), 
Z5 (r = 0.68), RF (r = 0.65), AX (r = 0.69) and the maximum fall in FEV1 (∆FEV1max) (P< 
0.001). A weak relationship was observed between R20 (r = 0.27), X5 (r = 0.37) and ∆FEV1max 
(P<0.01). Conclusion: Impulse oscillometry and spirometry do not concur precisely following 
indirect bronchoprovocation. However IOS detects additional cases of airway dysfunction in 
athletes and therefore may provide diagnostic value in this population. Further work is required 
to establish diagnostic thresholds and fully determine the place of IOS in screening athletes for 
airway dysfunction. 
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INTRODUCTION  
Airway dysfunction is prevalent in endurance athletes of all abilities (1, 2) and its detection is 
important in order to optimise respiratory health and athletic performance (3). In athletes, a 
variety of bronchoprovocation challenge tests have been recommended for the detection of 
airway dysfunction and/or to infer the presence of exercise-induced bronchoconstriction (4). 
However, regardless of the specific provocation methodology, the criteria employed to 
determine a ‘positive result’ is typically based on a change in airway function established by 
forced spirometry e.g. ≥10% reduction in forced expiratory volume in one second (FEV1) (5, 
6) .  
It is now accepted that a spirometric-based measurement can fail to detect the complex 
perturbations in airway function that can arise following a bronchoprovocation challenge (7) 
and in addition may be prone to influence from poor technique and respiratory muscle fatigue 
(8). Moreover, there appears to be a poor relationship between change in FEV1 following airway 
challenge and the presence of exertional symptoms in athletes (9). Therefore, the study and 
evaluation of other methods for assessing airway calibre and dynamic alterations in pulmonary 
function in this setting is required.   
Impulse oscillometry (IOS) is a non-effort dependent method of assessing airway function. 
Impulses generated by IOS are superimposed on tidal breathing and respiratory impedance is 
calculated by pressure and volume changes caused by impulses during the measurement. 
Respiratory impedance values are expressed over a range of impulse frequencies which can 
subsequently allow detection of the site of airway obstruction more precisely (10). In addition, 
IOS provides information regarding the elastic properties of the respiratory system.  
Impulse oscillometry has previously been utilised in athletic individuals to evaluate their airway 
function following bronchoprovocation (11, 12). Evans et al. (11) observed a change in airway 
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function following room temperature and cold air exercise challenges that would have 
otherwise remained undetected by spirometry. The conclusion from a series of studies (11-13) 
was that IOS yields greater sensitivity for detecting changes in airway function in athletes. 
These studies established diagnostic thresholds with one specific IOS parameter (i.e. ≥50% 
increase in respiratory resistance at 5 Hz) recommended as the most appropriate cut-off value 
when employed in conjunction with a EVH challenge (90% sensitivity; 80% specificity) to 
detect post-challenge airway obstruction (13).  
To date, the studies utilising IOS in athletes have been conducted in a highly selected population 
of symptomatic patients with a high pre-test probability of airway dysfunction. We therefore 
undertook this study with the aim of establishing the utility of IOS following indirect 
bronchoprovocation in a large cohort of recreational athletes screened for airway dysfunction. 
We compared the relationship between IOS and spirometry and utilised the described cut-offs 
to determine the prevalence of airway dysfunction. In addition, IOS and spirometry parameters 
were compared with respiratory symptoms. We selected eucapnic voluntary hyperpnoea (EVH) 
as the bronchoprovocation challenge since it is the test currently favoured by the International 
Olympic Committee-Medical Commission (IOC-MC) for diagnosing airway dysfunction in 
athletes (14).  
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METHODS 
Study population  
One hundred and one (male: n = 69) recreational athletes (mean ± SD: 6 ± 1 hours 
training/week) were recruited for this study. A variety of sporting disciplines were represented 
(endurance: n = 88; intermittent high-intensity: n = 9; strength: n = 4). All subjects were non-
smokers, and were free from respiratory, cardiovascular, metabolic and psychiatric disease, or 
any other significant medical condition except mild asthma. Twenty subjects had a prior 
physician diagnosis of clinical asthma; all were stable at time of study entry (i.e. no respiratory 
tract infection or change in medication for two weeks prior to inclusion) and all were prescribed 
short acting beta-2 agonist (SABA) with fourteen prescribed maintenance inhaled 
corticosteroid.  
Experimental design 
Subjects attended the laboratory on a single occasion to complete clinical assessment, 
pulmonary function measurements and a EVH challenge. Subjects were asked to refrain from 
strenuous exercise, caffeine and alcohol consumption on the day of testing. Subjects with 
asthma were asked to abstain from using short-acting inhaled beta-2 agonist and inhaled 
corticosteroids for 24 and 72 hrs, respectively, prior to the study. The study was approved by 
Northumbria University research ethics committee (Ethics ID: RE20-01-12590) and all subjects 
provided written informed consent for experimentation with human subjects.  
Clinical assessment  
Respiratory symptoms were determined via completion of the Dyspnoea-12 questionnaire (15). 
A sum of responses was calculated to determine the total score (scale range, 0 – 36; a high score 
indicating worse dyspnoea - mild: 1-12, moderate: 13-24, severe: 25-36). Subjects were 
classified as either asymptomatic (score: 0) or symptomatic (score: 1-36).  
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Pulmonary function measurement 
Spirometry 
Lung function was assessed by maximal forced flow-volume spirometry (MicroLoop ML3535; 
Cardinal Health, Basingstoke, UK) according to international guidelines (8), with established 
reference ranges employed (8).  
Impulse oscillometry 
Measures of respiratory impedance were obtained by impulse oscillometry (IOS) (MasterLab 
IOS System, Erich Jaeger Co., Wurzburg, Germany). In accordance with international 
recommendations (10) subjects performed 30 s of tidal breathing prior to maximal inspiration 
followed by passive expiration.  
Eucapnic voluntary hyperpnoea challenge 
A modified version of EVH was performed based on the protocol described previously (17, 
22). Briefly, subjects breathed a dry compressed gas mixture (21% O2, 5% CO2, balance N2) at 
a target ventilation rate equivalent to 85% (baseline FEV1 * 30) of their predicted maximal 
voluntary ventilation (MVV) for 6 min. Spirometry was performed at baseline and in duplicate 
at 3, 5, 7, 10 and 15-min post EVH.  Spirometric values within 5% were considered acceptable 
(8). Impulse oscillometry was performed pre and immediately post EVH.  A positive diagnosis 
of airway dysfunction was defined as a fall in FEV1 of ≥10% at two consecutive time points or 
≥50% increase in R5 post provocation. The maximum fall in FEV1 (∆FEV1max) was used for 
analysis.  
Statistical analysis 
Pulmonary function variables for airway dysfunction positive and negative subjects were 
compared using a two-way unpaired t-test. The relationship between spirometry and IOS 
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parameters were assessed using Pearson’s product-moment correlation coefficient (normally 
distributed data) (mean ± SD). A Spearman’s rank correlation was used to assess relationships 
between respiratory symptoms (i.e. Dyspnoea-12 score) and pulmonary function variables 
(median and range). Data was analysed using PASW Statistics 21 statistical software package 
(SPSS Inc., Version 21, Chicago, IL) and GraphPad Prism Version 5.0 (GraphPad Software, 
San Diego, California, USA). P<0.05 was considered statistically significant.  
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RESULTS 
Study population  
One hundred and one athletes consented to take part in the study. Seven athletes were excluded 
(n = 3; baseline airway obstruction and n = 4; unable to complete the EVH challenge). 
Consequently, ninety-four athletes (male: n = 64) completed the assessment (Table 1). 
Baseline pulmonary function  
All baseline pulmonary function measures were within normal predicted limits (Table 2). A 
direct relationship was observed between baseline FEV1, FVC and all IOS variables (P<0.05), 
with the exception of X5 (P>0.05). Baseline FEV1/FVC displayed no relationship with any IOS 
parameter.  
Neither spirometry nor IOS parameters at baseline were predictive of the ΔFEV1max (P>0.05). 
Likewise baseline spirometry did not differentiate between airway dysfunction positive and 
negative athletes, however resting X5 was lower (P<0.01) and AX was higher (P<0.05) in airway 
dysfunction positive (i.e. ≥10% fall in FEV1) compared to negative athletes respectively.  
Clinical assessment 
Exercise associated respiratory symptoms (e.g. cough, wheeze, dyspnoea etc.) were reported 
by forty-five athletes (48%) (mild: 91%; moderate: 9%). Nineteen athletes (95%) with a prior 
diagnosis of asthma were symptomatic (mild:  85%; moderate: 15%).  
A poor relationship was observed between respiratory symptoms (i.e. Dyspnoea-12 score) and 
∆FEV1max (r = 0.12) and all post challenge IOS parameters; R20 (r = 0.18), X5 (r = 0.08), RF (r 
= 0.18), AX (r = 0.14) (P>0.05), R5 (r = 0.26), Z5 (r = 0.25) (P<0.05) (Figure 1). However, those 
with a positive diagnosis of airway dysfunction based on ΔFEV1max were more likely to be 
symptomatic (75%) in comparison to IOS cut-off values (65%) (Figure 2).  
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Airway response to eucapnic voluntary hyperpnoea 
The EVH target ventilation was calculated as 121.0 ± 23.9 L.min-1.  The achieved ventilation 
rate was 101.0 ± 27.8 L.min-1 (range: 42.9 – 155.1 L.min-1) (predicted: 83.2 ± 35.4%). Eighty-
seven athletes (93%) met their target ventilation (i.e. minute ventilation ≥60% MVV) thus 
achieving test validation (16). When the athletes who failed to achieve their target ventilation 
were excluded from the analysis (n = 7), the relationship between ∆FEV1max and IOS variables 
remained similar (data not shown). 
Sixteen athletes (17%) were positive for airway dysfunction based on spirometric assessment 
(ΔFEV1 max = -18.9 ± 10.7%). Only seven athletes with a prior diagnosis of asthma had a 
positive EVH result (i.e. ≥10% fall in FEV1). When based on an IOS cut-off (i.e. ≥50% increase 
in R5), seventeen athletes (18%) had evidence of airway dysfunction. Therefore when based on 
either FEV1 or R5 cut-off values, twenty-four athletes (26%) had evidence of airway 
dysfunction. However, only nine athletes (10%) were diagnosed with airway dysfunction based 
on both diagnostic thresholds (i.e. FEV1 and R5 cut-off values did not identify the same 
patients). Post-EVH values for all IOS values were higher for athletes with airway dysfunction 
(P<0.01) (Table 3). 
Spirometry vs. Impulse oscillometry 
A direct relationship was observed between percentage change in R5 (r = 0.65), Z5 (r = 0.68), 
RF (r = 0.65), AX (r = 0.69) and ∆FEV1max (P<0.001). A weak relationship was observed 
between change in R20 (r = 0.27), X5 (r = 0.37) and ∆FEV1max, respectively (P<0.01) (Figure 
3). When the athletes whose ∆FEV1max ≥25% were excluded from the analysis (n = 2), the 
relationship between ∆FEV1max and IOS variable remained similar (data not shown). 
Moreover, in athletes who were not previously prescribed ICS (n = 80), the relationships 
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remained unchanged; R5 (r = 0.67), Z5 (r = 0.68), RF (r = 0.69), AX (r = 0.68) and ∆FEV1max, 
respectively (P<0.001) and R20 (r = 0.34), X5 (r = 0.31) and ∆FEV1max (P<0.01).  
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DISCUSSION  
The accurate detection of airway dysfunction is important in order to optimise the health and 
performance of athletes. The present study indicates that the application of IOS in conjunction 
with an indirect bronchoprovocation challenge identifies abnormalities in airway function that 
would otherwise have remained undetected if only spirometry was performed. This finding has 
important implications for the utility of IOS in clinical practice and its potential application as 
a non-volitional means for identifying bronchoconstriction in athletes.   
The prevalence of airway dysfunction in our cohort of recreational athletes when utilising a 
spirometric cut-off value (i.e. ≥10% fall in FEV1) was 17% and similar to previous work in a 
comparable population (>13%) (17). Similarly, when employing a previously published IOS 
cut-off value (i.e. ≥50% increase in R5) (13) a prevalence of 18% was observed. However 
importantly, only 10% of athletes met both diagnostic thresholds. Indeed only moderate 
correlations were observed between change in R5, Z5, RF and AX and weak correlations between 
R20 and X5 and ∆FEV1max respectively. This discrepancy in diagnostic methodologies 
highlights a potential for misdiagnosis of both athletes with and without airway dysfunction. 
Indeed the implications of over and under-diagnosis of airway dysfunction have previously 
been raised in elite level athletes (18).  
In agreement with previous findings (11, 12), neither resting spirometry nor IOS correlated 
with ∆FEV1max; supporting the recommendation that bronchoprovocation testing is required 
to confirm a diagnosis of airway dysfunction in athletes (19). However, interestingly we found 
significantly lower resting X5 and higher resting AX values in athletes with airway dysfunction. 
Whilst speculative, this may imply that patients with airway dysfunction have more rigid 
airways which might contribute to low-grade airway remodelling as a consequence of airway 
injury (20).  
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The present study highlights a similar relationship between IOS and spirometry following 
indirect bronchoprovocation as described previously (11, 12). However a number of important 
differences between studies should be acknowledged. In contrast to our screened cohort of 
athletes, Evans and colleagues (11, 12) only recruited subjects with “probable EIB” as 
determined by a “maximal fall of ≥7% in FEV1” following EVH, with variability in severity of 
bronchoconstriction not considered. Indeed 64% of their cohort had a previous physician 
diagnosis of asthma, with all subjects reporting symptoms suggestive of airway dysfunction 
during and post exercise. In addition, peak percentage change in FEF50 was the principal 
variable shown to correlate with resistance of the airways determined by IOS. However, the 
use of mid-expiratory flow has been previously highlighted as insufficiently sensitive to 
diagnose airway dysfunction reliably in athletic populations (21).  
Although Rundell et al. (13) reported strong correlations between IOS variables (resistance and 
reactance) and ∆FEV1max following EVH, the study consisted of only twenty subjects with (n 
= 10) and without (n = 10) a previous diagnosis of airway hyper-responsiveness (AHR). In 
addition, the average reduction in lung function following EVH for individuals with a positive 
diagnosis was significantly greater (30.6%) i.e. moderate severity in contrast to only mild 
severity (18.9%) in the present study. More specifically, 30% of athletes in the study by Rundell 
et al. were classified as having moderate to severe airway dysfunction whereas the majority of 
positive athletes (88%) in the current study were classified as only mild airway dysfunction 
(i.e. ≥10 - <25% FEV1). In addition, a mean fall of 4.5% in FEV1 for negative athletes was 
observed which is comparable with prior literature (22).  
The diagnostic threshold recommended by the IOC-MC when employing EVH in athletes is 
currently ≥10% reduction in FEV1 post challenge (14). However, it has been argued that this 
cut-off value may not provide optimum diagnostic accuracy (5) with poor short-term test re-
test reproducibility recently observed (23). Interestingly, when employing a 15% reduction in 
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FEV1 as the diagnostic cut-off in the present study, IOS detected 88% of positive athletes. 
Moreover, when a 20% reduction in FEV1 was employed IOS detected 100% of positive 
athletes (i.e. spirometry and IOS detected the same patients). The possibility that the 
relationship between IOS and spirometry improves as the severity of airway dysfunction 
increases is therefore consistent with our findings and previous research (13). In addition, this 
observation suggests that performing a solitary IOS measure immediately post provocation in 
athletes with greater severity bronchoconstriction (i.e. ≥15% fall in FEV1) accurately detects 
airway dysfunction. This finding supports the concept that IOS may provide greater sensitivity 
when employed with an indirect bronchoprovocation challenge (11, 12).   
Although we have shown that IOS does not concur precisely with spirometry in identifying 
athletes with mild airway dysfunction, the application of IOS appears to identify additional 
individuals with an underlying airway abnormality. Therefore whilst our findings do not 
support the sole use of IOS in diagnosing airway dysfunction, they do provide a strong 
argument for IOS as an adjunctive tool. In addition, the utility of IOS in populations unable to 
perform forced breathing manoeuvres (i.e. paediatric populations) (24, 25) or in providing a 
common differential diagnosis, such as exercise-induced laryngeal obstruction, should not be 
overlooked (26).   
No clear relationship was found between respiratory symptoms and presence of airway 
dysfunction as detected by changes in either spirometry or IOS. Although this is a common 
observation in studies that have employed spirometry to objectively assess airway dysfunction 
(27), this is the first study to evaluate respiratory symptoms against changes in IOS in athletes. 
The discrepancy observed may be in part explained by the general perception of breathing 
discomfort when approaching maximal exercise (5). This finding provides further evidence for 
the poor prognostic value of respiratory symptoms in athletes (27).  
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In order to differentiate between ‘normal’ exertional breathlessness associated with increasing 
exercise intensity and abnormal respiratory symptoms suggestive of airway dysfunction, recent 
studies have focussed on the ‘perception’ of symptoms in athletes and non-athletes following 
indirect bronchoprovocation (i.e. EVH and methacholine). However only minor differences in 
perception of bronchoconstriction-related symptoms were observed between groups (9). The 
explanation between the presence of classic airway-centric symptoms (i.e. chest tightness) 
suggestive of airway dysfunction and physiological airway changes (i.e. increased work of 
breathing) in athletic populations therefore remains to be determined and warrants further work.  
Methodological considerations/future research  
At present there is no specific guidance in the relevant Respiratory Society statements (4) 
regarding the optimum protocol when utilising IOS for the diagnosis of airway dysfunction in 
athletes. Our findings highlight that IOS may detect airway dysfunction from a solitary 
measurement post challenge in athletes with moderate to severe airway dysfunction. Therefore 
whilst future studies may wish to provide a direct comparison between IOS and spirometry at 
several time points post EVH, it is more appropriate to establish diagnostic thresholds based on 
the mean plus two or three standard deviations of the response in healthy subjects (28). Future 
studies should therefore apply this principle to IOS in conjunction with the traditional indirect 
bronchoprovocation measures in order to be able to establish cut-off values to be employed in 
clinical practice. 
Conclusion 
In conclusion, in a large screened cohort of athletes, we have demonstrated that although IOS 
does not concur precisely with spirometry, it does detect additional athletes with evidence of 
airway dysfunction. This highlights the potential utility of IOS as a supplementary measure in 
detecting airway dysfunction in athletes. Furthermore our findings emphasise the poor 
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relationship between respiratory symptoms and objective testing. Future work is required to 
establish diagnostic thresholds in order to determine the role and overall utility of IOS in 
detecting athletes for airway dysfunction.  
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TABLE HEADINGS 
 
 
Table 1. Subject clinical characteristics. 
 
Definitions of abbreviations: BMI, body mass index. 
 
 
 
Table 2. Baseline pulmonary function. 
Definitions of abbreviations: FEV1, Forced expiratory volume in 1-s; FVC, Forced vital 
capacity; R5, Resistance at 5 Hz; R20, Resistance at 20 Hz; X5, Reactance at 5Hz; Z5, Magnitude 
of impedance at 5 Hz; RF, Resonance frequency, AX, Area of reactance (area integrated from 
5Hz to RF). 
 
 
 
Table 3. Impulse oscillometry values post eucapnic voluntary hyperpnoea. 
 
Definitions of abbreviations: R5, Resistance at 5 Hz; R20, Resistance at 20 Hz; X5, Reactance 
at 5Hz; Z5, Magnitude of impedance at 5 Hz; RF, Resonance frequency, AX, Area of reactance 
(area integrated from 5Hz to RF). 
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Table 1.  
 
 
 
Variables  
Sex (M:F)  64 : 30 
Age (years)  32 ± 9 
Height (cm)  174.2 ± 8.8 
Weight (kg)  73.7 ± 12.6 
BMI (kgm-2)  24.2 ± 3.0 
Training (hrswk-1)  6 ± 1 
Data presented as Mean ± SD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
22 
 
Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as Mean ± SD. *P<0.05; ** (P<0.01) denotes difference between 
airway dysfunction negative and positive athletes. Note: positive athletes 
determined based on current guidelines (i.e. ∆FEV1max).  
 
  
Variables Airway dysfunction 
 Negative   Positive 
FEV1 (L)  4.02 ± 0.81  4.12 ± 0.74 
FEV1 (% predicted)  105.1 ± 9.5   101.0 ± 9.5 
FVC (L)  4.89 ± 0.95  5.19 ± 0.85 
FVC (% predicted)  108.3 ±  11.1  106.7 ± 10.2 
FEV1/FVC (%)  82.2 ± 5.6  79.5 ± 7.5 
R5 (kPaL-1s-1)          0.24 ± 0.06          0.27 ± 0.07 
R20 (kPaL-1s-1)    0.22 ± 0.06          0.24 ± 0.05 
X5 (kPaL-1s-1)         -0.08 ± 0.05         -0.14 ± 0.12** 
Z5 (kPaL-1s-1)          0.26 ± 0.06          0.29 ± 0.08 
RF (Hz)        10.57 ± 2.76        11.62 ± 3.16 
AX (Hz. kPaL-1s-1)          0.21 ± 0.14          0.34 ± 0.32* 
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Table 3.  
 
 
 
 
 
 
 
 
 
Data presented as Mean ± SD. ** (P<0.01) denotes difference between 
airway dysfunction negative and positive athletes. 
  
Variables Airway dysfunction 
 Negative Positive 
R5 (kPaL-1s-1)  0.30 ± 0.09   0.43 ± 0.14** 
R20 (kPaL-1s-1)  0.25 ± 0.06   0.30 ± 0.07** 
X5 (kPaL-1s-1) -0.09 ± 0.04  -0.14 ± 0.10** 
Z5 (kPaL-1s-1)   0.32 ± 0.09   0.46 ± 0.16** 
RF (Hz) 13.20 ± 3.86 20.36 ± 6.94** 
AX (Hz. kPaL-1s-1)   0.37 ± 0.31   1.32 ± 1.09** 
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FIGURE LEGENDS  
 
Figure 1. Relationship between Dyspnoea-12 score and (a) maximum fall in FEV1; (b) 
resistance at 5Hz post eucapnic voluntary hyperpnoea.  
 
 
Figure 2. Venn diagram depicting the association between respiratory symptoms and objective 
evidence of airway dysfunction.  
 
 
Figure 3.  Resistance at 5 Hz (a); Resistance at 20 Hz (b); Reactance at 5Hz (c); Magnitude of 
impedance at 5 Hz (d); Resonance frequency (e), Area of reactance (f) vs. maximum fall in 
FEV1 post eucapnic voluntary hyperpnoea. Broken vertical line represents abnormal lung 
function (i.e. ≥10% fall in FEV1). 
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